MJA
MJA

Patient-centred management of inflammatory arthritis: more than just disease control

Louisa Chou, Andrew M Briggs and Anita E Wluka
Med J Aust 2017; 206 (5): . || doi: 10.5694/mja16.01248
Published online: 20 March 2017

It is important that patients’ broader health needs are addressed

Rheumatoid arthritis and seronegative spondyloarthropathies are the most common types of inflammatory arthritis. They cause pain, joint damage and progressive functional loss, which limit participation in life and constitute a significant disease burden.1,2 Over the past decades, great advances in management, with the availability of corticosteroids, synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs, have significantly improved the disease control and outcomes. The guidelines, whose algorithms focus on drug prescription to achieve remission of disease,3,4 support everyday treatment. However, while they provide direction for the use of DMARDs, they do not consider the patients’ broader health needs.

Online responses are no longer available. Please refer to our instructions for authors page for more information.